Results 191 to 200 of about 16,542 (247)

Tezepelumab in Chinese Patients With Severe Chronic Rhinosinusitis With Nasal Polyps: A Prespecified Subgroup Analysis of the Phase 3 WAYPOINT Trial

International Forum of Allergy &Rhinology, Volume 16, Issue 11, Page 1309-1317, November 2026.
ABSTRACT Background Chronic rhinosinusitis with nasal polyps (CRSwNP) in Chinese patients often exhibits a mixed Type 1/2/3 inflammatory phenotype (63%), potentially impacting the efficacy of biologics targeting Type 2 inflammation. This prespecified subgroup analysis of WAYPOINT (NCT04851964) evaluated the efficacy and safety of tezepelumab in Chinese
Li Hu, Houyong Li, Xicai Sun, Quan Liu, Yu Xu, Jiangang Fan, Andrew Foster, Claudia Chen, Yun Chon, Dehui Wang   +9 more
wiley   +1 more source

Efficacy of Biologics in Aspirin Exacerbated Respiratory Disease. [PDF]

Clin Transl Allergy
Priessnitz JK, Hagopian A, Patev AJ, Han JK, Lam KK.   +4 more
europepmc   +1 more source

Efficacy and Predictors of Response to Biologic Therapy and Endoscopic Sinus Surgery in Patients With Nasal Polyps: A Systematic Review

International Forum of Allergy &Rhinology, Volume 16, Issue 11, Page 1342-1351, November 2026.
ABSTRACT Background Biologics and endoscopic sinus surgery (ESS) treat refractory chronic rhinosinusitis with nasal polyposis (CRSwNP), but direct comparisons are lacking. We synthesized efficacy and subgroup data across randomized controlled trials (RCTs) of biologics and ESS.
Arun Chakravorty, Matthew E. Lin, Rory Lubner, Jess C. Mace, Jeffrey Suh, Jivianne Lee, Marilene Wang, Sarah Wise, Naweed Chowdhury, Zachary M. Soler, Justin Turner, Timothy L. Smith, Myung Sim, Daniel M. Beswick   +13 more
wiley   +1 more source

Effectiveness and renal safety of dupilumab in the treatment of moderate-to-severe atopic dermatitis patients with chronic kidney disease stages 4-5: a real-world cohort study in China. [PDF]

Front Med (Lausanne)
Hu G, Zhang Q, Yang L, Hu Y, Chen J.
europepmc   +1 more source

Effect of Dupilumab on Allergen-Specific IgE Levels and Clinical Tolerance in Patients with Food Allergy: A Systematic Review. [PDF]

Int J Mol Sci
Grześk-Kaczyńska M, Kaczyński S, Kosztulska B, Rydzyńska M, Rosada T, Ukleja-Sokołowska N.   +5 more
europepmc   +1 more source

Pharmacokinetics and safety of tezepelumab in children with mild, moderate or severe asthma and adolescents with mild‐to‐moderate asthma

British Journal of Clinical Pharmacology, Volume 92, Issue 11, Page 3819-3830, November 2026.
Abstract Aim Tezepelumab is a human monoclonal antibody that blocks the activity of thymic stromal lymphopoietin and is approved for adolescents and adults with severe asthma. This analysis assessed pharmacokinetics (PK), pharmacodynamics and safety of tezepelumab up to 85 days postdose in adolescents and children.
Anna Lundahl, Jonathan Grigg, Lubna Abuqayyas, Piotr Kuna, Gillian Hunter, Beata Pawlikowska, Jacob Leander, Michael Levin, Atul Gupta, James Paton, Katharine C. Pike, Jane R. Parnes, Gun Almqvist, Stephanie L. Roseti, on behalf of the study investigators   +14 more
wiley   +1 more source

Skin Deep: A Case Report of Erythema Nodosum Induced by Dupilumab Therapy. [PDF]

Cureus
Tasnim N, Bawa J, Alhashimi R, Malana E, Kaur J, Sayeed N, Khan A.   +6 more
europepmc   +1 more source

Longitudinal Proteomic Signatures of Dupilumab and Tralokinumab Treated Atopic Dermatitis Patients. [PDF]

Clin Transl Allergy
Francuzik W, Pažur K, Worm M.
europepmc   +1 more source